Vaccinex To Report Topline Data For SIGNAL-AD Phase 1b/2 Trial Of Pepinemab In Alzheimer's Disease At The Alzheimer's Association International Conference, Philadelphia, July 31, 2024

Author: Benzinga Newsdesk | July 17, 2024 08:11am

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present topline data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer's disease at the Alzheimer's Association International Conference in Philadelphia, July 28- Aug 1, 2024. Eric Siemers, MD, Principal Investigator, will present results of the study in a Featured Research Session.

Posted In: VCNX